Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $18.25

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) have been given an average rating of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $18.25.

Several brokerages have recently commented on IMMX. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Mizuho increased their price target on shares of Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Citizens Jmp restated a “market outperform” rating and set a $23.00 price objective on shares of Immix Biopharma in a research report on Friday, March 27th. HC Wainwright upped their target price on Immix Biopharma from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. Finally, Morgan Stanley started coverage on Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 target price for the company.

Immix Biopharma Stock Performance

IMMX opened at $8.94 on Friday. Immix Biopharma has a 52-week low of $1.34 and a 52-week high of $11.61. The firm has a market cap of $473.55 million, a P/E ratio of -10.04 and a beta of 0.20. The business’s fifty day moving average is $8.16 and its 200-day moving average is $5.52.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.12). On average, research analysts predict that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP acquired a new position in Immix Biopharma during the fourth quarter worth about $30,000. Velan Capital Investment Management LP bought a new stake in shares of Immix Biopharma during the 2nd quarter valued at approximately $52,000. Mathes Company Inc. acquired a new position in Immix Biopharma during the 4th quarter worth approximately $56,000. Balyasny Asset Management L.P. bought a new position in Immix Biopharma in the 4th quarter valued at approximately $67,000. Finally, Kera Capital Partners Inc. acquired a new stake in Immix Biopharma in the fourth quarter valued at approximately $68,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.